טוען...
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial...
שמור ב:
| הוצא לאור ב: | Respir Res |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6339432/ https://ncbi.nlm.nih.gov/pubmed/30658649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0968-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|